Twenty-Four Months Follow-Up of Intravitreal Bevacizumab Injection Versus Intravitreal Triamcinolone Acetonide Injection for the Management of Persistent Non-Infectious Uveitic Cystoid Macular Edema

• Published in: Ocular immunology and inflammation Vol. 27; no. 2; pp. 294 - 302
• Main Authors: Lasave, Andrés F., Schlaen, Ariel, Zeballos, David G., Díaz-Llopis, Manuel, Couto, Cristóbal, El-Haig, Wael M., Arevalo, J. Fernando
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 17.02.2019
• Subjects: Adult; Aged; Angiogenesis Inhibitors - administration & dosage; Bevacizumab; Bevacizumab - administration & dosage; Female; Follow-Up Studies; Glucocorticoids - administration & dosage; Humans; Intravitreal Injection; Intravitreal Injections; Macula Lutea - pathology; Macular Edema - diagnosis; Macular Edema - drug therapy; Macular Edema - etiology; Male; Middle Aged; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone Acetonide; Triamcinolone Acetonide - administration & dosage; Uveitic Cystoid Macular Edema; Uveitis - complications; Uveitis - diagnosis; Uveitis - drug therapy; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity; Young Adult; Uveitic Cystoid Macular Edema; Triamcinolone Acetonide; Intravitreal Injection; Bevacizumab
• ISSN: 0927-3948; 1744-5078
• DOI: 10.1080/09273948.2017.1400073

Purpose: To report the efficacy of intravitreal bevacizumab (IVB) injection versus intravitreal triamcinolone acetonide (IVT) for persistent non-infectious uveitic cystoid macular edema (CME). Methods: Interventional retrospective comparative case series evaluated 37 consecutive patients (44 eyes) with completely controlled uveitis and recalcitrant CME. Patients received repeated injections of 1.25 mg of IVB or 4 mg of IVT. Results: Best-corrected visual acuity (BCVA) at baseline and 24 months was logMAR 1 and 0.8 respectively, in the IVB group (p = 0.002) and; logMAR of 1.1 and 0.6, in the IVT group (p = 0.001). Central macular thickness at baseline and 24 months was 399.2 µm and 333.7 µm (p < 0.0009), respectively, for the IVB group and; 464.4 µm and 316.5 µm in the IVT group (p = 0.044). Postoperatively, IOP increased in the IVT group. Conclusions: Repeated injections with IVT improve BCVA as effectively as repeated injections with IVB in the long-term management of persistent uveitic CME.